The interaction research of biomolecules provides important reference data for drug discovery, and greatly promotes the screening and development of novel therapeutic drugs. Enzyme Fragment Complementarity Assay (EFCA) provides a reliable research method for this process. This synergy between this methodology and genetics of complex trait genetics opens up new ways to study the molecular etiology of human diseases and promote their prevention and treatment.
Studies have found that if some intact protein is divided into two fragments, both fragments will lose activity. But when their positions are close enough, specific non-covalent complementation will occur and reassemble into a complete protein to perform its function. Based on this, scientists have developed an enzyme fragment complementary system based on reporter proteins (such as β-galactosidase, dihydrofolate reductase, and luciferase). EFC reasonably divides the reporter protein into two fragments, which act as enzyme acceptors (EA, large fragment) and enzyme donors (ED, small fragment). Individually, these fragments are inactive. But if they approach and assemble due to the interaction of the target proteins X and Y, they form an active enzyme that hydrolyzes its substrate to generate a biochemical signal.
Creative Proteomics is a professional biotechnology company with nearly two decades of experience in molecular interaction research. We recruited many biochemical and genetic experts to jointly build a powerful and efficient EFCA platform. Our researchers can choose different functional proteins, such as luciferase and fluorescent protein, according to customers' different needs. On this platform, customers can discover the mechanism of action (MOA), measure and rank ligand potencies, perform binding and functional screening, identify novel compounds, and more.
Customers can choose different technology platforms according to project requirements, or contact us directly for consultation, and our expert team will provide you with customized experimental procedures.
Creative Proteomics is an international biotechnology company dedicated to research in molecular interactions and other related fields. The enzyme fragment complementation platform we constructed has the characteristics of high quality and efficiency, and the data obtained can be directly used for paper publication. Our one-stop service aims to save customers time and money.